NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) — DDC Enterprise Limited (NYSE American: DDC) (“DDC” or the “Company”), a global Asian food platform and digital asset treasury company, today announced that its Board of Directors has approved a reverse share split of the Company’s Class A ordinary shares at a ratio of 1-for-7.99 (the “Reverse Share Split”), pursuant to the reverse share split authority approved by shareholders at the Company’s shareholders meeting on June 29, 2026.

The Reverse Share Split will become effective as of 12:01 a.m. (Eastern Time) on November 30, 2026. The Class A ordinary shares are expected to begin trading on a split-adjusted basis on NYSE American at the market open on November 30, 2026, under the existing symbol “DDC” and the new CUSIP number G276AC135.

The Company’s shareholders approved the Reverse Share Split at the shareholders meeting held on June 29, 2026. They authorized the Company’s Board of Directors to determine the final ratio, up to 1-for-10, and the effective date. The Reverse Share Split was subsequently authorized by the Board of Directors on November 17, 2026. The Reverse Share Split is intended to increase the per-share trading price of the Class A ordinary shares and support the Company’s continued compliance with NYSE American continued listing standards.

At the effective time, every 7.99 issued and outstanding Class A ordinary shares will automatically be combined into one Class A ordinary share. The par value will increase from US$0.40 to US$3.196 per share. The Reverse Share Split will reduce the number of outstanding Class A ordinary shares from approximately 68.17 million to approximately 8.53 million. The number of authorized Class A ordinary shares will be reduced by the same ratio. The Company’s Class B ordinary shares are not subject to the Reverse Share Split.

No fractional shares will be issued. Fractional entitlements will be rounded down to the nearest whole share. Apart from the treatment of fractional shares, the Reverse Share Split affects all holders of Class A ordinary shares uniformly and will not change any holder’s percentage ownership of Class A ordinary shares. Proportionate adjustments will be made to the Company’s outstanding preferred shares, convertible notes, warrants, options and other equity awards, if any, in accordance with their terms.

Shareholders who hold their shares in book-entry form or through a bank, broker or other nominee do not need to take any action. Their positions will be adjusted automatically, subject to their brokers’ processes. Holders of share certificates will receive instructions from the Company’s transfer agent, Equiniti Trust Company, LLC.

About DDC Enterprise Limited

DDC Enterprise Limited (NYSE American: DDC) is a global Asian food platform and digital asset treasury company. The Company operates a portfolio of leading Asian food brands that generated $39.2 million in fiscal year 2025 revenue with first-time positive Adjusted EBITDA, and it holds one of the largest corporate Bitcoin treasuries among NYSE-listed consumer companies. DDC is led by Founder, Chairwoman, and Chief Executive Officer Norma Chu. For more information, visit www.ddc.xyz.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events, including the anticipated effective date of the reverse share split, the expected commencement of split-adjusted trading, and the Company’s continued listing on NYSE American, and are subject to risks and uncertainties. These statements can be identified by words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential,” or “continue.” Actual results could differ materially, including as a result of the risk that NYSE American may delist the Company’s Class A ordinary shares, the risk that trading in the Company’s Class A ordinary shares may be suspended by NYSE American, and general market and economic conditions. Additional risks that may affect the Company are described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 20-F. The Company undertakes no obligation to update or revise any forward-looking statements except as required by law.

Media & Investor Contacts

Investor and Media Relations:
pr@ddc.xyz

HONG KONG, Nov. 20, 2026 (GLOBE NEWSWIRE) — Smart Logistics Global Limited (Nasdaq: SLGB) (the “Company”), a Hong Kong-based business-to-business contract logistics solution provider, today reported its financial results for the six months ended June 30, 2026.

Financial highlights:

  • Revenue for the six months ended June 30, 2026 was RMB230.6 million (US$34.0 million), compared with RMB332.8 million for the same period in 2025. The decrease primarily reflected softer transportation demand across several industrial sectors served by the Company during the period.
  • Gross profit was RMB9.7 million (US$1.4 million), compared with RMB17.7 million in the prior-year period. Gross profit margin decreased to 4.2% from 5.3% reflecting lower transportation volumes despite continued pricing discipline and cost-efficiency initiatives.
  • Operating loss was RMB7.2 million (US$1.1 million), compared with operating income of RMB8.8 million in the first half of 2025. The current period included a non-cash share-based incentive expense of RMB6.8 million recorded in selling and marketing expenses.
  • Net loss was RMB10.9 million for the six months ended June 30, 2026, compared with net income of approximately RMB5.8 million for the same period in 2025. The change primarily reflected the operating factors described above, including lower transportation volumes and the recognition of approximately RMB6.8 million in non-cash share-based compensation expense, together with an increase in income tax expense of approximately RMB0.7 million for the period. Excluding the impact of the non-cash share-based compensation expense, the Group recorded a net loss excluding share-based compensation to consultants of approximately RMB4.1 million for the period.
  • Cash was RMB 2.1 million (USD 0.3 million) as of June 30, 2026.
  • Total assets were RMB 209.1 million (USD 30.8 million); total shareholder’s equity remained stable at RMB 133.8 million (USD 19.7 million).

Recent Operational Highlights:

Transportation Activity Reflected Sector Conditions:
The number of waybills, total kilometers travelled and tonnage transported decreased by 32%, 34% and 28%, respectively, compared with the same period last year, consistent with softer demand in paper, steel, food and coal-related logistics.

Sector-Specific Volume Trends:
Internal operating data for January–June 2026 showed year-on-year declines across major sectors, including paper (-26.21%), steel (-30.57%), food and other (-6.09%), and coal (-82.25%), broadly in line with national freight indicators and weaker procurement activity in these industries.

Gross Margin Reflects Lower Volumes:
Pricing discipline, route optimization and cost-efficiency measures partially mitigated the effect of lower shipment activity, with gross profit margin of 4.2% compared with 5.3% in the prior-year period.

Expansion of Trucker Network:
Registered truckers in the Group’s Transportation Management System increased from approximately 160,000 as of December 31, 2025 to over 170,000 as of the date of this report, strengthening fulfillment capacity and network resilience.

Launch of Cross-Border Trading Platform:
In September 2026, the Group completed the first operation of its cross-border non-ferrous metals trading platform through the Xuzhou Jiabin Supply Chain Center, including the initial aluminum scrap import from Vietnam and the signing of a long-term supply agreement with an overseas resource partner.

Strategic Platform Integration:
The industrial raw-materials logistics platform and the non-ferrous metals trading platform are intended to complement each other, with logistics capacity supporting trading flows and trading activity potentially generating additional freight volumes over time. Management believes this integrated model can create additional cross-selling opportunities and strengthen the Company’s supply chain ecosystem.

Chairman’s Statement

Dear Shareholders,

During the first half of 2026, overall economic conditions in China remained stable, but demand in several industrial sectors softened. While national GDP grew year-on-year, domestic consumption expanded at a slower pace and investment-related activities, including manufacturing and real estate, declined. These sector-specific trends resulted in more moderate transportation demand across the industries we serve.

Our operating metrics reflected this environment. The number of waybills, total kilometers travelled and tonnage transported all decreased compared with the same period last year, consistent with more cautious procurement and shipment patterns among industrial customers. Despite lower volumes, gross margin remained stable due to continued pricing discipline, route optimization and cost-efficiency measures.

In September 2026, the Group completed the first operation of its cross-border non-ferrous metals trading platform through the Xuzhou Jiabin Supply Chain Center. This initial aluminum scrap import from Vietnam and the signing of a long-term supply agreement represent an early step in developing the trading platform, which is intended to operate alongside our existing logistics network and complement our industrial raw-materials logistics capabilities.

We will continue to focus on operational efficiency, disciplined execution and prudent financial management. While demand in certain sectors may fluctuate, the Group remains committed to supporting customers’ logistics needs and advancing the development of both the industrial logistics platform and the non-ferrous metals trading platform.

The period also included a non-cash share-based incentive expense related to a consultant engagement supporting the development and promotion of our commodity trading and logistics business. Excluding this item, our normalized income from operations remained positive, reflecting the resilience of our operating model.

On behalf of the Board, I thank our shareholders, customers, partners and employees for their continued support.

Chairman, Hue Kwok Chiu

About Smart Logistics Global Limited

Smart Logistics Global Limited (Nasdaq: SLGB) was established in 2017 and is a China-focused industrial logistics and supply chain company. Its businesses include B2B contract logistics, industrial raw-material transportation, and digital supply chain management.

The Company operates a self-developed TMS, an approximately 110,000-square-meter modern logistics park in Fuzhou, Jiangxi Province, and seven full-truck logistics service centers in China. The Xuzhou Jiabin Supply Chain Center, established by the Company in northern China, supports the industrial logistics platform and the cross-border non-ferrous metals trading platform.

Website: https://www.smartlogisticsglobal.com/

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may”, “will”, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Investor Relations Contact
Andrew Barwicki
516-662-9461 / andrew@barwicki.com

TEL AVIV, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) — ZOOZ Strategy Ltd. (Nasdaq & TASE: ZOOZ) (the “Company”) announced today that its Board of Directors has approved an extension of the Company’s existing share repurchase program of up to $50 million of the Company’s outstanding ordinary shares (the “Repurchase Program”), for an additional 12-month period (the “Extended Term”) under the same terms, such that the Company shall be authorized to repurchase during the Extended Term up to $48,519,274 of the Company’s outstanding ordinary shares, remaining under the Repurchase Program, as extended, subject to meeting applicable regulatory requirements.

The Repurchase Program, as extended, will allow the Company to repurchase its ordinary shares from time to time using a variety of methods, including open market purchases, negotiated transactions or otherwise, all subject to applicable law. The Repurchase Program, as extended, will not obligate the Company to acquire any particular amount of ordinary shares, and the Repurchase Program may be suspended or discontinued at any time at the Company’s discretion.

“When our shares trade below the value of the bitcoin and cash behind each one, buying them back is one of the most accretive uses of our capital. Extending this program gives us the flexibility to act on that discount whenever it appears, increasing every remaining shareholder’s ownership of our bitcoin holdings while we continue to pursue the opportunities that build long-term value,” said Jordan Fried, Chief Executive Officer of ZOOZ Strategy Ltd.

As of November 20, 2026, the Company has acquired a total of 178,530 ordinary shares for a total purchase price of $1,480,726 under the Repurchase Program.

As of November 20, 2026, the Company holds 1046.96 Bitcoin worth $66,791,920.

About ZOOZ

ZOOZ is the first Nasdaq and TASE dual-listed company implementing a long-term bitcoin treasury strategy. The Company is pioneering an innovative approach to capital allocation by holding bitcoin as a strategic asset, offering shareholders asymmetric, long-term exposure to bitcoin while maintaining financial and regulatory standards. The ZOOZ Ordinary Shares are publicly traded on Nasdaq and TASE under the ticker: ZOOZ.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements”. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include statements regarding the Repurchase Program, as extended, implementation and execution of the Repurchase Program, as extended, including its timing, its terms and any repurchases that may be made thereunder, the execution of the Company’s Bitcoin treasury strategy and the potential value to shareholders. These forward-looking statements are based on ZOOZ’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause ZOOZ’s future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the impacts of macroeconomic conditions, heightened inflation and uncertain credit and financial markets, on ZOOZ’s business and financial position; changes in expected or existing competition; changes in the regulatory environment; unexpected litigation or other disputes; risks related to the Bitcoin treasury strategy; the risk that ZOOZ’s share price may be highly correlated to the price of the Bitcoin that it holds; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; general market, political, and economic conditions in the countries in which ZOOZ operates, including Israel; and the effect of the evolving nature of the recent war in Israel. Other factors that may cause ZOOZ’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in ZOOZ’s annual report on Form 20-F filed with the SEC on March 27, 2026, and in other filings that ZOOZ makes and will make with the SEC in the future. ZOOZ expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

For Media Inquiries:

ZOOZ Media Relations

Eran Gabay Exponent IR – eran@exponentir.com

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, November 23, 2026

WATERTOWN, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BROADEN2 Phase 2b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, November 23, 2026. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.

To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be available following the event. 

About KT-621
KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is currently in clinical development in AD and asthma. KT-621 has the potential to transform treatment paradigms by offering a safe, effective, oral option for millions of patients worldwide living with Type 2 diseases, such as AD, asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), prurigo nodularis (PN), and bullous pemphigoid (BP), among others.

About Kymera Therapeutics 
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

Investor Contact: 
Justine Koenigsberg
investors@kymeratx.com
857-285-5300 

Media Contact:
Matthew Henson
media@kymeratx.com
857-285-5300

CEDAR RAPIDS, Iowa, Nov. 20, 2026 (GLOBE NEWSWIRE) — Today, the board of directors of United Fire Group, Inc. (UFG) (Nasdaq: UFCS) declared a common stock quarterly cash dividend of $0.20 per share. This dividend will be payable December 18, 2026, to shareholders of record as of December 4, 2026.

UFG has a long history of paying quarterly dividends dating back to March 1968.

About UFG

Founded in 1946 as United Fire & Casualty Company, UFG, through its insurance company subsidiaries, is engaged in the business of writing property and casualty insurance. The company is licensed as a property and casualty insurer in 50 states and the District of Columbia, and is represented by approximately 850 independent agencies. AM Best assigns a rating of “A-” (Excellent) for members of the United Fire & Casualty Group. For more information about UFG, visit www.ufginsurance.com.

Contact:

Investor relations
Email: ir@unitedfiregroup.com

Media inquiries
Email: news@unitedfiregroup.com

Disclosure of forward-looking statements

This release may contain forward-looking statements about our operations, anticipated performance and other similar matters. The Private Securities Litigation Reform Act of 1995 provides a safe harbor under the Securities Act of 1933 and the Securities Exchange Act of 1934 for forward-looking statements. The forward-looking statements are not historical facts and involve risks and uncertainties that could cause actual results to differ from those expected and/or projected. Such forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company, the industry in which we operate, and beliefs and assumptions made by management. Words such as “expect(s),” “anticipate(s),” “intend(s),” “plan(s),” “believe(s),” “continue(s),” “seek(s),” “estimate(s),” “goal(s),” “remain(s) optimistic,” “target(s),” “forecast(s),” “project(s),” “predict(s),” “should,” “could,” “may,” “will,” “might,” “hope,” “can” and other words and terms of similar meaning or expression in connection with a discussion of future operations, financial performance or financial condition, are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Information concerning factors that could cause actual outcomes and results to differ materially from those expressed in the forward-looking statements is contained in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 26, 2026. The risks identified in our Annual Report on Form 10-K and in our other SEC filings are representative of the risks, uncertainties, and assumptions that could cause actual outcomes and results to differ materially from what is expressed in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release or as of the date they are made. Except as required under the federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.  In addition, future dividend payments are within the discretion of our Board of Directors and will depend on numerous factors, including our financial condition, our capital requirements and other factors that our Board of Directors considers relevant.

NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the closing of its previously announced underwritten public offering of 13,269,231 shares of its common stock at a public offering price of $13.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,730,769 additional shares of common stock. The aggregate gross proceeds to SELLAS from this offering were $172.5 million before deducting underwriting discounts and commissions and offering expenses. Investors in the offering included new healthcare-focused institutional investors.

J.P. Morgan and TD Cowen acted as the lead book-running managers for the offering. Mizuho also acted as a book-running manager for the offering. A.G.P./Alliance Global Partners and Maxim Group LLC acted as lead managers for the offering.

The public offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-294504) that was previously filed with the Securities and Exchange Commission (the “SEC”) on March 20, 2026, and became automatically effective upon filing. The preliminary prospectus supplement and accompanying base prospectus and the final prospectus supplement relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. The offering was made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmorganchase.com and postsalemanualrequests@broadridge.com; or TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has the potential as a monotherapy and combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing SLS009 (tambiciclib), a small molecule CDK9 inhibitor, for the treatment of AML in patients with unfavorable prognostic factors including ASXL1 mutation, commonly associated with poor prognosis in various myeloid diseases.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the public offering. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties, including the risks and uncertainties inherent in SELLAS’ business, including those described in the company’s periodic filings with the SEC. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 19, 2026 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made.

Investor Contact

John Fraunces
Managing Director
LifeSci Advisors, LLC
jfraunces@lifesciadvisors.com

Media Contact

Joan Bosisio
VP, Scientific & Medical Communications
Simpson Healthcare
jbosisio@simpsonhealthcare.com

Source: SELLAS Life Sciences Group, Inc.

WAYNE, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 52,000 shares of common stock (the “Options”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The Options were granted on November 18, 2026, and have an exercise price of $6.70 per share, which is equal to the closing price of Avalo’s common stock on the grant date. The Options will vest as to 25% of the underlying shares of common stock on the one-year anniversary of the applicable employee’s start date of employment, and the balance of the underlying shares of common stock vesting monthly thereafter over 36 months, subject to the applicable employee’s continued service relationship with Avalo through the applicable vesting dates. The Options are subject to the terms and conditions of Avalo’s 2025 Inducement Award Plan and award agreements thereunder.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: drug development costs, timing of trials and trial results and other risks, including reliance on investigators and enrollment of patients in clinical trials; reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in Avalo’s filings with the Securities and Exchange Commission, available at www.sec.gov. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Avalo expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Avalo’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries
Jonathan Neely
VP, Head of Investor Relations
jneely@avalotx.com

or

Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com

Cootamundra, Australia, Nov. 20, 2026 (GLOBE NEWSWIRE) — Australian Oilseeds Holdings Limited (Nasdaq: COOT) (the “Company”) today announced that it received a notification letter dated November 17, 2026 (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”), which requires listed companies to maintain stockholders’ equity of at least $2,500,000. The Notice states that the Company’s Annual Report on Form 20-F for the fiscal year ended June 30, 2026 (the “Annual Report”) reported stockholders’ equity of $(4,359,873), below the $2,500,000 required by the Equity Rule, and that, as of November 17, 2026, the Company does not meet the alternative continued listing standards of a market value of listed securities of at least $35 million or net income from continuing operations of at least $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years. The Annual Report presents the Company’s financial statements in Australian dollars and reported a total deficit of AUD 6,335,275 as of June 30, 2026.

Under Nasdaq rules, the Company has until January 4, 2027 to submit a plan to regain compliance with the Equity Rule. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice, or until May 16, 2027, for the Company to evidence compliance. The Company intends to submit a plan to regain compliance within the period provided by Nasdaq. There can be no assurance that Nasdaq will accept the Company’s plan or that the Company will regain compliance with the Equity Rule.

The Notice has no immediate effect on the Company’s listing on The Nasdaq Capital Market, and during the grace period, as may be extended, the Company’s ordinary shares and warrants will continue to trade on Nasdaq under the symbols “COOT” and “COOTW”.

About Australian Oilseeds Holdings Limited

Australian Oilseeds Holdings Limited (Nasdaq: COOT) is a Cayman Islands exempted company that conducts its core business through its majority-owned UK subsidiary, which operates the RentBuddyUK platform. RentBuddyUK is focused on the UK rental market, providing digital rent guarantee solutions that help international students, overseas residents and young professionals secure rental housing, while offering rent protection solutions to landlords and property management agencies. Through an online application, verification and risk assessment process, RentBuddyUK aims to build a more efficient, transparent and convenient rent guarantee service model connecting tenants, landlords and real estate service providers.

In addition, through a wholly owned subsidiary, the Company operates a technology services business focused on property technology and digital management solutions.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s ability to regain compliance with Nasdaq continued listing requirements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in the Company’s Annual Report on Form 20-F for the fiscal year ended June 30, 2026 and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Investor Contact

Mr. Jacky Wen
Board Secretary
Australian Oilseeds Holdings Limited
jacky@cootglobal.com

New assays suggest extensive mineralized halos surrounding the main sulphide accumulation, highlighting potential for greater bulk-tonnage scale

OTTAWA, Nov. 20, 2026 (GLOBE NEWSWIRE) — Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) (“Viridian” or the “Company”) reports additional near-surface copper-nickel-cobalt mineralization at its Kraken project in Labrador, including 21.2 metres at 0.62% CuEq in an extension of hole VKS25-026. The latest results continue to demonstrate broad, consistent mineralization across Kraken Main, with assays pending from 16 additional holes, including holes with substantial visually identified sulphide-rich intervals.

Highlights

  • Strong copper-nickel-cobalt mineralization extended: Hole VKS25-026E returned 21.2 metres grading 0.62% CuEq, extending previously reported mineralization.
  • Mineralization from surface: Hole VKS25-057 returned 24.45 metres at 0.18% CuEq within the mineralized halo overlying the main sulphide accumulation. Assays remain pending from the final 21 metres, which contain most of the visually identified patchy net-textured sulphides, with only the final 5 metres of the reported interval intersecting the upper portion of this mineralization.
  • Broad near-surface mineralization continues: Additional holes returned 43.05 metres grading 0.16% CuEq and 23.3 metres grading 0.20% CuEq, supporting the widespread distribution of mineralization across Kraken Main.
  • Fully funded 2027 resource program: Following the closing of a first tranche of financing for proceeds of $5.77 million, Viridian is preparing for its maiden resource drilling program, with 16 holes still awaiting assay results and an updated Exploration Target planned for January 2027.

Tyrell Sutherland, President and CEO of Viridian Metals, commented:

“The consistency of broad mineralization beginning almost at surface continues to be one of Kraken’s most compelling attributes. These latest results suggest that substantial mineralized halos may extend beyond the main sulphide accumulation, potentially adding significant scale to an already large system. With much of our 2026 drilling still awaiting assays, we believe we are only beginning to establish the full extent of Kraken Main.

“Following our recently completed $5.77 million financing, we are fully funded for our 2027 maiden resource drilling program. Our focus is now shifting toward establishing the scale of the resource and evaluating how Kraken’s near-surface geometry and substantial mineralized thicknesses could translate into a large-scale, low-cost mining operation.”

Kraken Main Zone 2026 drill hole locations, with cross-section showing the full drill trace of VKS25-057, highlighting the reported 24.45-metre mineralized interval and the underlying sulphide-rich interval with assays pending. Drill holes from this release are in orange. Reported intervals represent downhole lengths; true thicknesses are not yet known. Intercept lengths and grades have been rounded to one decimal place.

Figure 1: Kraken Main Zone 2026 drill hole locations, with cross-section showing the full drill trace of VKS25-057, highlighting the reported 24.45-metre mineralized interval and the underlying sulphide-rich interval with assays pending. Drill holes from this release are in orange. Reported intervals represent downhole lengths; true thicknesses are not yet known. Intercept lengths and grades have been rounded to one decimal place.

Drilling Continues to Demonstrate Broad, Consistent Near-Surface Mineralization

The latest assay results (Table 1) continue to demonstrate broad, near-surface mineralization across Kraken Main. The results include an extension of previously reported mineralization in VKS25-026, which returned a total interval of 21.2 metres grading 0.62% CuEq from top of bedrock at 5.05 metres depth. Additional results include 43.05 metres grading 0.16% CuEq in VKS26-052 and 23.3 metres grading 0.20% CuEq in VKS25-059, in both cases from top of bedrock beneath less than 3 metres of overburden.

Partial assays from VKS25-057 returned 24.45 metres grading 0.18% CuEq from the top of bedrock at 1.45 metres depth, including 5.9 metres grading 0.28% CuEq, with the highest grades at the base of the reported interval. This interval was logged as disseminated sulphides, with an average assay-derived sulphide content of 4.3% and is interpreted as a mineralized halo overlying the main sulphide accumulation (Figure 1). The remaining 21 metres contain long intervals of patchy net-textured sulphides, indicating that the principal sulphide accumulation lies within the interval awaiting assays.

The results from VKS25-057 suggest that broad halos of lower-grade mineralization may surround the principal mineralized horizon. Other broad, lower-grade intersections, including 43.05 metres grading 0.16% CuEq in VKS26-052, may similarly represent mineralized halos above or below the main sulphide accumulation rather than the principal horizon itself. Further drilling and geological interpretation are required to establish these relationships.

The potential presence of broad mineralized halos surrounding the principal sulphide accumulation could increase the scale of the bulk-tonnage opportunity at Kraken Main. Given the near-surface geometry of the system, additional mineralized intervals have favourable implications for potential strip ratios and mining costs. A larger mineralized envelope would provide greater flexibility in mine planning, with the potential to optimize production rates and operating margins.

The 2026 drill program was designed to establish the continuity of near-surface mineralization across Kraken Main and demonstrate consistent mineralized thicknesses exceeding 30 metres, more than three times the average thickness identified by the initial Exploration Target (see news release dated September 15, 2026, available on the Company’s SEDAR+ profile at www.sedarplus.ca and website at www.viridianmetals.com). The latest results complement previously reported mineralized intervals exceeding 50 metres, providing further evidence of a broad mineralized system extending across widely separated portions of the Main Zone.

With assays outstanding from 16 additional holes, including substantial intervals of visually identified patchy net-textured sulphides along the southern extension of Kraken Main, significant portions of the 2026 drilling program remain to be evaluated. The broad distribution of near-surface mineralization continues to support the Company’s bulk-tonnage exploration model, while the remaining results will help establish the grade, thickness and continuity of mineralization ahead of the planned January 2027 Exploration Target update.

Table 1 – Kraken Main 2026 drill results. New results are in bold.

Drillhole ID From To Length* Cu Ni Co CuEq¹
  (m) (m) (m) (%) (%) (%) (%)
VKS25-024 1.0 51.15 50.15 0.19 0.26 0.04 0.68
including 12.2 31.0 18.8 0.33 0.43 0.06 1.12
including 19.4 31.0 11.6 0.3 0.5 0.07 1.28
VKS25-026 – extended 5.05 26.25 21.2 0.21 0.21 0.03 0.62
VKS26-052 0.7 43.75 43.05 0.05 0.05 0.01 0.16
including 0.7 3.0 2.3 0.07 0.13 0.03 0.46
and including 7.5 15.0 7.5 0.06 0.06 0.01 0.18
and including 23.0 24.7 1.7 0.09 0.07 0.02 0.25
and including 26.3 29.15 2.85 0.05 0.11 0.02 0.28
and including 35 43.75 8.75 0.05 0.06 0.01 0.17
VKS26-053 1.5 5.0 3.5 0.05 0.08 0.02 0.21
VKS26-054 0.7 4.0 3.3 0.36 0.67 0.11 1.68
and 11.7 13.0 1.3 0.65 0.81 0.11 2.18
and 17.45 18.75 1.3 0.44 0.83 0.11 2.01
and 20.7 26.9 6.2 0.38 0.57 0.08 1.50
VKS25-025 21.0 44.05 23.05 0.07 0.09 0.01 0.24
VKS25-055 1.0 4.0 3.0 0.07 0.07 0.01 0.2
VKS26-060 14.4 37.4 23.0 0.13 0.15 0.03 0.44
including 14.4 25.25 10.85 0.22 0.25 0.04 0.72
VKS26-062 9.8 50.6 40.8 0.23 0.2 0.03 0.63
including 9.8 24.85 15.7 0.39 0.36 0.06 1.09
including 9.8 17.00 7.2 0.44 0.22 0.03 1.30
VKS25-056 3 16.05 no significant intercepts
VKS25-057 – Partial 1.45 25.9 24.45 0.07 0.05 0.01 0.18
including 1.45 9.1 7.65 0.05 0.06 0.01 0.18
and including 20 25.9 5.9 0.13 0.08 0.01 0.28
VKS25-058 – abandoned 1.55 7.05 5.5 0.05 0.05 0.01 0.17
VKS25-059 2.2 25.5 23.3 0.06 0.06 0.02 0.20
including 2.2 13.5 11.3 0.08 0.08 0.02 0.25

*True thickness of the reported mineralized intervals is not yet known. Reported interval lengths represent downhole core lengths and should not be interpreted as true thickness.

Intercepts are calculated using a 0.1% CuEq¹ cut-off grade corresponding to approximately US$10 NSR with no more than 5 m of internal dilution. Viridian has completed specific gravity measurements and full multi-element geochemical analysis on all samples to support ongoing characterization of the Kraken system.

Drilling Update

The holes reported in this release were prioritized for laboratory analysis in October. Additional samples from holes VKS26-061, VKS26-063-70, and VKS25-057E, which were drilled along the 4.5km length of the Main Zone have been delivered to Activation Laboratories Ltd. (“Activation Labs”) in Ancaster, Ontario, with assays pending. Additional holes VKS26-071-74 and extension holes VKS25-041e, VKS25-042e, and VKS25-046e have been processed and will be delivered to the lab in the coming days. All assays from the remaining 16 holes are expected to be received by the end of the year.

Results also remain outstanding from holes spaced approximately 500 metres apart along a further 2.5 kilometres of Kraken Main to the south, including previously reported visually identified patchy net-textured sulphide intervals of 41.8 and 47.3 metres. Laboratory assays are required to establish the grades of these intervals.

Viridian completed 33 drill holes during its 2026 exploration program. Both rigs have been mobilized off site and the Company’s focus will now shift to reporting results, metallurgical analysis and interpretation in preparation for an update to the Exploration Target in January 2027. The Company has issued initial requests for proposals (RFPs) for its 2027 resource drilling program.

Table 2 – Kraken Main Zone 2026 drill collars. Collar coordinates are reported in NAD83 / UTM Zone 20N. Azimuths are referenced to true north. Bold holes are included in this release.

Hole Easting (m) Northing (m) Azimuth (°) Dip (°) Total Depth (m) Status
VKS25_024E 446090 6020686 112 72 51.15 Final assay
VKS25_025E 446087 6020630 105 70 44.05 Final assay
VKS25_026E 446040 6020656 110 75 33.70 Final assay
VKS26_052 446028 6020269 90 73 30.65 Final assay
VKS26_053 446020 6020363 100 77 11.10 Final assay
VKS26_054 446139 6020413 102 78 30.90 Final assay
VKS26_055 446018 6020364 90 80 48.15 Final assay
VKS26_056 446151 6020068 100 78 15.30 Final assay
VKS26_057 446036 6019894 90 80 46.90 Partial assay
VKS26_058 445981 6019803 90 80 7.00 Final assay
VKS26_059 445983 6019798 91 80 30.50 Final assay
VKS26_060 446194 6019234 90 80 37.40 Final assay
VKS26_061 446045 6018677 80 76 4.85 Submitted
VKS26_062 446194 6019409 91 80 50.60 Final assay
VKS26_063 446046 6018679 105 77 55.75 Submitted
VKS26_064 446043 6018274 57 77 35.00 Submitted
VKS26_065 446208 6016973 84 65 51.15 Submitted
VKS26_066 446116 6017321 91 79 31.70 Submitted
VKS26_067 446100 6017275 91 80 20.00 Submitted
VKS26_068 447889 6012515 90 80 30.50 Submitted
VKS26_069 447884 6012478 125 60 30.50 Submitted
VKS26_070 445528 6020119 70 70 50.05 Submitted
VKS26_071 445864 6020466 86 78 51.20 Submitted
VKS26_072 446191 6020919 89 79 36.75 Shipping
VKS25_042E 446029 6020974 108 70 51.15 Shipping
VKS25_049E 446116 6020834 102 80 18.5 Abandoned
VKS25_046E 446070 6020879 102 73 50.1 Shipping
VKS2_073 446207 6020825 90 75 15.40 Shipping
VKS2_074 446001 6020790 92 84 17.0 Shipping


QA/QC

On receipt from the drill site BTW-sized drill core was systematically logged for geological attributes, photographed and sampled at Viridian’s Core Shack at Kraken Camp. Sample lengths as small as 0.30 m were used to isolate features of interest, but most samples within moderate to strong mineralization were 0.5-1.0 m in length. Core was cut in half lengthwise along a pre-determined line, with one half (same half, consistently, dictated by cut line where present) collected for analysis and one half stored as a record. Standard reference materials and blanks were inserted by Viridian personnel at regular intervals into the sample stream. Bagged samples were sealed with security tags to ensure integrity during transport. They were delivered by expeditor to Activation Labs’ facility in Ancaster, ON.

Activation Labs is independent of Viridian and accredited to ISO/IEC 17025. Samples (up to 7 kg) were dried and crushed to 80% passing 2 mm, then riffle split (250 g) and pulverized to 95% passing 105 µm (code RX1). A four-acid near-total digest with an inductively coupled plasma optical emission spectroscopy (ICP-OES) finish was used for 35-element analysis on 25 g sample pulps (code 1F2). Samples that were over the analyses limit for Co, Cu and Ni were reanalyzed using sodium peroxide fusion ICP (code 8-peroxide).

Qualified Person

Tyrell Sutherland, P.Geo., President and CEO of Viridian Metals and a Qualified Person as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and approved the technical disclosure contained in this news release. Mr. Sutherland is not independent of the Company.

¹Copper Equivalent Calculation

CuEq¹ calculated based on the following metal prices (USD): $4.00/lb Cu, $7.50/lb Ni and $15.00/lb Co, and a recovery of 80% for Ni and Co, consistent with comparable projects. The Company believes that all metals included in the CuEq¹ calculation have a reasonable potential to be recovered. CuEq¹ values are provided for illustrative purposes only; actual recoveries and metal prices may differ materially from those assumed.

Correction to November 17, 2026 News Release

The Company also wishes to correct the disclosure of finder’s fees in its news release dated November 17, 2026, announcing the closing of the first tranche of its non-brokered private placement (the “Private Placement”). That news release incorrectly stated that the Company paid cash finder’s fees of $102,076.80 and issued 130,260 finder’s warrants (the “Finder’s Warrants”) in connection with the first tranche. The Company in fact paid cash finder’s fees of $265,276.77 and issued 335,583 Finder’s Warrants to certain arm’s length finders in connection with the first tranche, in accordance with the policies of the CSE.

Each Finder’s Warrant entitles the holder to acquire one common share of the Company at an exercise price of $1.05 per share for a period of 24 months from the date of issuance, subject to acceleration on the same terms as the warrants issued as part of the hard dollar units. The Finder’s Warrants are subject to a statutory hold period expiring March 18, 2027. All other information in the November 17, 2026, news release remains unchanged.

About Viridian Metals

Viridian Metals is a pioneer and leader in generative metal exploration with a focus on environmental responsibility and ethical practices. Founded with the intention of discovering new critical metals deposits with the potential to transform the metal supply chain. We leverage innovative technologies and methods to enhance efficiency and sustainability in jurisdictions eager to be leaders in supplying the energy transition. Viridian maintains expertise in a range of critical metals with a primary focus on copper, nickel and cobalt in the near term. Our commitment to integrity and transparency fosters strong partnerships with both local and global stakeholders.

The Company’s common shares trade on the Canadian Securities Exchange under the symbol “VRDN” and on the OTCQB under the symbol “VIRMF”.

For further information, please contact:

Viridian Metals
Tyrell Sutherland
CEO
Telephone: (613) 884-8332
Email: Info@viridianmetals.com

The CSE has not reviewed, approved or disapproved the contents of this news release

Cautionary Statement Regarding Forward-Looking Information

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Viridian with respect to future business activities and operating performance.

Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the foregoing) be taken, occur, be achieved, or come to pass.

Forward-looking information in this news release includes, but is not limited to, statements regarding: (i) the scope, timing and funding of the Company’s 2027 resource drilling program at the Kraken Copper-Nickel Project, and the expectation that the Company is fully funded for that program; (ii) the timing of processing and delivery of samples to Activation Labs, and the timing and content of assay results from holes not yet reported, including the remaining interval of hole VKS25-057, the holes and extensions identified under “Drilling Update” above and the southern step-out holes along a further 2.5 kilometres of Kraken Main, and the expectation that all remaining samples will be delivered to the laboratory by the end of 2026; (iii) the expectation that visually identified sulphide mineralization will be confirmed by laboratory analysis; (iv) the targeting of an updated Exploration Target in January 2027 incorporating results from the 2026 drilling program; (v) the potential for a mineral resource estimate to be prepared at Kraken Main at some future date; (vi) the Company’s interpretations, including statements by management, regarding the geometry, continuity, thickness and depth extent of the mineralized horizon at Kraken Main, including true thicknesses of reported intervals, the potential for localized higher-grade zones within the broader mineralized system, the potential presence and extent of mineralized halos surrounding the principal sulphide accumulation and their potential contribution to the scale of Kraken Main, the potential scale of Kraken Main, including as it relates to potential open-pit development, and the potential to expand mineralization through extension and step-out drilling; (vii) the metal prices, metallurgical recoveries and other assumptions underlying the copper-equivalent calculations disclosed herein, and the expectation that the metals included in those calculations have a reasonable potential to be recovered; (viii) the business plans and expectations of Viridian; and (ix) expectations for other economic, business and/or competitive factors in respect of Viridian.

In particular, readers are cautioned that there has been insufficient exploration at the Kraken Main Zone to define a mineral resource, and it is uncertain whether further exploration will result in any target being delineated as a mineral resource. There is no certainty that a mineral resource will be defined at Kraken Main. Visual estimates of sulphide mineralization are preliminary and are not a substitute for laboratory analysis. Copper-equivalent values are provided for illustrative purposes only and no metallurgical testwork has been completed at Kraken Main; actual recoveries may differ materially from the assumptions used.

Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involves known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of Viridian to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to Viridian, including information obtained from third-party industry analysts and other third-party sources, and are based on management’s current expectations or beliefs. Any and all forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Forward-looking information reflects Viridian’s current beliefs and is based on information currently available to it and on assumptions it believes to be not unreasonable in light of all of the circumstances. In some instances, material factors or assumptions are discussed in this news release in connection with statements containing forward-looking information. Such material factors and assumptions include, but are not limited to: the availability of drill rigs, qualified personnel and contractors on the timelines anticipated; the ability to obtain and maintain all required permits, surface access rights and Indigenous and community consents to conduct the planned program; weather, site access and logistical conditions in Labrador remaining consistent with the Company’s expectations; the accuracy of the Company’s geological models and the Company’s interpretations of prior drilling, geophysical surveys and modelled conductor plates; the continued availability of financing and working capital to fund the program through to completion; commodity prices for copper, nickel and cobalt remaining at levels supportive of the program; the absence of material adverse changes in applicable laws, regulations or political conditions; the ongoing conflicts in Ukraine and the Middle East and any actions taken by other countries in response thereto, such as sanctions or export controls; and anticipated and unanticipated costs and other factors referenced in the Company’s continuous disclosure record available on SEDAR+, including, but not limited to, those set forth in the Filing Statement under the caption “Risk Factors”. Although Viridian has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking information contained herein is made as of the date of this news release and, other than as required by law, Viridian disclaims any obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/35ba8d33-6029-4e9e-8004-9c51173ffc60

SINGAPORE, Nov. 20, 2026 (GLOBE NEWSWIRE) — Fitness Champs Holdings Limited (“Fitness Champs Holdings”, “FCHL” or the “Company”) (NASDAQ: FCHL), a distinguished aquatic sports education provider in Singapore, today announced that the closing of its previously announced best-efforts public offering (the “Offering”) with gross proceeds to the Company expected to be approximately $5 million, before deducting placement agent fees and other estimated expenses payable by the Company, excluding any proceeds from the exercise of the Warrants (as defined below). The Company intends to use the net proceeds from this Offering for business expansion, general working capital purposes and other general corporate purposes. The Company believes that, as a result of the Offering, it has regained compliance with the stockholders’ equity requirement of The Nasdaq Stock Market LLC (“Nasdaq”) to address the previously reported deficiency, as discussed further below.

The Offering

The Offering is comprised of 14,285,715 units (each a “Unit”), consisting of one Class A ordinary share of the Company, par value $0.00225 per share (the “Class A Ordinary Shares”), or in lieu thereof, a pre-funded warrant, and one warrant to purchase one Class A Ordinary Share (each, a “Warrant”). The public offering price of the Units is $0.35 per Unit. Each of the Warrants has an exercise price of $1.02 per Class A Ordinary Share and be exercisable beginning immediately upon issuance and will expire on the six-month anniversary of the issuance date.

We are registering 14,285,715 Class A Ordinary Shares underlying the Pre-Funded Warrants and 14,285,715 Class A Ordinary Shares underlying the Warrants. Each of the Pre-Funded Warrants will have an exercise price of $0.00225 per Class A Ordinary Share and will be immediately exercisable (subject to the beneficial ownership limitation) and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.

A holder of the Warrants may, at any time and in its sole discretion, exercise its Warrants in whole or in part by means of a “zero exercise price” option. As a result of this feature, we do not expect to receive any cash proceeds from the exercise of the Warrants because it is highly unlikely that a Warrant holder will elect to pay an exercise price in cash to receive Class A Ordinary Shares when they could elect the “zero exercise price” option in these circumstances to receive more Class A Ordinary Shares than they would receive if they did pay an exercise price. Under the zero-exercise price option, a holder of a Warrant will receive up to fifteen (15) Class A Ordinary Shares for each Warrant without paying any exercise price to us. It is anticipated that all Warrant holders will utilize the zero-exercise price option as this allows for the exercise of the Warrants for no additional consideration and will result in a greater number of Class A Ordinary Shares that investors will receive upon exercise than what would be issuable upon cash exercise or cashless exercise. As a result, there is no practical or financial incentive for holders of the Warrants to exercise the Warrants via cash exercise or cashless exercise and we do not expect to receive any proceeds from the exercise of the Warrants overall. If all 14,285,715 Warrants are exercised under the zero-exercise price option, we would issue an aggregate of 214,285,725 Class A Ordinary Shares for no additional consideration.

Univest Securities, LLC is acting as sole placement agent for the offering.

The securities described above were offered by the Company pursuant to a registration statement on Form F-1 (File No. 333-299806), as amended, and declared effective by the Securities and Exchange Commission (the “SEC”) on November 13, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The Offering was made only by means of a written preliminary prospectus and final prospectus that will form a part of the registration statement. The final prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus relating to this offering may be obtained, when available, by contacting Univest Securities, LLC at info@univest.us, or by calling +1 (212) 343-8888.

Stockholders’ Equity Requirement

As previously reported on a Form 6-K, on May 26, 2026, the Company received a letter from Nasdaq indicating that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), because (i) the stockholders’ equity of the Company of $598,490 as of December 31, 2025, as reported in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025, was below the minimum stockholders’ equity requirement of $2,500,000 (the “Nasdaq Equity Requirement”) and (ii) the Company did not, as of May 26, 2026, meet the alternatives standards of market value of listed securities or net income from continuing operations for compliance with Nasdaq Listing Rules 5550(b)(2) and 5550(b)(3), respectively. The Company submitted a plan to regain compliance and was granted 180 calendar days from May 26, 2026 (or until November 20, 2026), to evidence compliance.

Based on the proceeds of funds from the Offering, the Company believes that, as of the date of this press release, it has stockholders’ equity in excess of the Nasdaq Equity Requirement. However, the final determination of compliance is subject to review and approval by Nasdaq. If at any time during the next periodic report the Company does not evidence compliance, the Company may be subject to delisting.

If, at the time of the Company’s next periodic report, the Company is deemed by Nasdaq not to be in compliance, the Company would have the right to request a hearing before a Nasdaq hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance that, if the Company does appeal any delisting determination that such appeal would be successful.

While the Company believes it now is compliance with the Nasdaq Equity Requirement, if Nasdaq determines it is not in compliance, the Company will take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq. There can be no assurance that Nasdaq will determine that the Company (i) has regained compliance with the Nasdaq Equity Requirement, (ii) will maintain compliance with the Nasdaq Equity Requirement, or (iii) will maintain compliance with the other Nasdaq continued listing requirements or be successful in appealing any delisting determination.

About Fitness Champs Holdings Limited

Fitness Champs Holdings Limited is a distinguished aquatic sports education provider, offering general swimming lessons to children and adults, with ladies-only swimming lessons available, as well as aquatic sports classes such as competitive swimming and lifesaving. The Company is one of the largest providers of swimming lessons to children enrolled in public schools under the Ministry of Education of Singapore in Singapore through the SwimSafer program, and has been offering private swimming lessons to children, youths and adults under its brand “Fitness Champs” since 2012. The Company aims to make swimming an enjoyable and affordable sport for children and adults, for water safety and as a way of keeping fit and healthy. Fitness Champs also plans to grow into a diversified sports education provider by expanding its offerings to include other sports such as pickleball. For more information, please visit the Company’s website at https://ir.fitnesschamps.sg/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, but not limited to, statements regarding the Company’s anticipated use of proceeds from the Offering, the Company’s belief that it has regained compliance with the Nasdaq Equity Requirement, Nasdaq’s determination as to such compliance, the Company’s ability to maintain compliance with the Nasdaq Equity Requirement and other Nasdaq continued listing requirements, any potential exercise of the Warrants, and the Company’s plans to expand its offerings. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, including the expectation that . Investors can identify many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Factors that could cause actual results to differ materially include, among others, Nasdaq’s review of the Company’s compliance, the Company’s ability to maintain sufficient stockholders’ equity, including as a result of future operating losses, the Company’s ability to deploy the net proceeds of the Offering as anticipated, and the other risks described under “Risk Factors” in the final prospectus relating to the Offering and in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025.The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For investor and media inquiries, please contact:
Email: ir@fitnesschampsaquatics.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.